Stratos Wealth Partners’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.48M Buy
9,719
+133
+1% +$20.4K 0.02% 656
2025
Q4
$1.32M Sell
9,586
-696
-7% -$91.1K 0.01% 669
2025
Q3
$1.32M Buy
10,282
+1,154
+13% +$141K 0.02% 655
2025
Q2
$1.1M Sell
9,128
-941
-9% -$106K 0.01% 662
2025
Q1
$1.12M Sell
10,069
-2,316
-19% -$247K 0.02% 617
2024
Q4
$1.21M Sell
12,385
-64
-0.5% -$6.83K 0.02% 626
2024
Q3
$1.43M Sell
12,449
-902
-7% -$102K 0.02% 553
2024
Q2
$1.42M Buy
13,351
+945
+8% +$94.9K 0.02% 540
2024
Q1
$1.2M Sell
12,406
-1,007
-8% -$103K 0.02% 588
2023
Q4
$1.35M Buy
13,413
+227
+2% +$21.9K 0.03% 514
2023
Q3
$1.34M Buy
13,186
+909
+7% +$92.3K 0.03% 476
2023
Q2
$1.24M Sell
12,277
-648
-5% -$64.8K 0.03% 471
2023
Q1
$1.19M Sell
12,925
-731
-5% -$63.8K 0.03% 437
2022
Q4
$1.24M Buy
13,656
+1,178
+9% +$99.2K 0.03% 451
2022
Q3
$948K Sell
12,478
-799
-6% -$66.2K 0.03% 497
2022
Q2
$1.12M Buy
13,277
+1,523
+13% +$134K 0.03% 478
2022
Q1
$1.03M Sell
11,754
-175
-1% -$15.2K 0.02% 542
2021
Q4
$1.04M Buy
11,929
+181
+2% +$15K 0.02% 549
2021
Q3
$961K Buy
11,748
+32
+0.3% +$2.88K 0.02% 534
2021
Q2
$1.07M Sell
11,716
-994
-8% -$88.5K 0.03% 524
2021
Q1
$1.09M Sell
12,710
-751
-6% -$67.4K 0.03% 474
2020
Q4
$1.27M Sell
13,461
-2,137
-14% -$187K 0.04% 391
2020
Q3
$1.36M Sell
15,598
-1,301
-8% -$113K 0.04% 327
2020
Q2
$1.48M Buy
16,899
+4,542
+37% +$392K 0.05% 306
2020
Q1
$1.02M Buy
12,357
+3,076
+33% +$274K 0.05% 323
2019
Q4
$879K Sell
9,281
-700
-7% -$62.8K 0.03% 425
2019
Q3
$867K Sell
9,981
-91
-0.9% -$8.17K 0.04% 404
2019
Q2
$920K Sell
10,072
-1,792
-15% -$152K 0.04% 392
2019
Q1
$1.02M Buy
11,864
+139
+1% +$11.2K 0.05% 358
2018
Q4
$902K Buy
11,725
+500
+4% +$38.9K 0.05% 351
2018
Q3
$867K Sell
11,225
-712
-6% -$52.6K 0.04% 366
2018
Q2
$808K Sell
11,937
-32,579
-73% -$2.25M 0.04% 413
2018
Q1
$3.23M Buy
44,516
+887
+2% +$67.5K 0.14% 156
2017
Q4
$3.28M Sell
43,629
-4,031
-8% -$304K 0.15% 145
2017
Q3
$3.67M Buy
47,660
+3,149
+7% +$238K 0.17% 128
2017
Q2
$3.33M Sell
44,511
-10,096
-18% -$716K 0.17% 132
2017
Q1
$3.63M Buy
54,607
+3,400
+7% +$227K 0.21% 111
2016
Q4
$3.34M Buy
51,207
+13,054
+34% +$847K 0.21% 109
2016
Q3
$2.7M Buy
38,153
+3,592
+10% +$262K 0.18% 114
2016
Q2
$2.56M Buy
34,561
+6,965
+25% +$481K 0.19% 106
2016
Q1
$1.79M Buy
27,596
+12,207
+79% +$830K 0.15% 124
2015
Q4
$1.19M Sell
15,389
-385
-2% -$30.6K 0.1% 161
2015
Q3
$1.3M Buy
15,774
+4,113
+35% +$366K 0.16% 115
2015
Q2
$1.03M Sell
11,661
-1,188
-9% -$109K 0.13% 149
2015
Q1
$1.13M Buy
12,849
+56
+0.4% +$4.97K 0.13% 156
2014
Q4
$1.06M Buy
12,793
+1,632
+15% +$135K 0.19% 127
2014
Q3
$941K Buy
11,161
+565
+5% +$45.7K 0.22% 106
2014
Q2
$862K Buy
+10,596
New +$833K 0.29% 103

Other funds holding NVS

Stratos Wealth Partners's NVS Position: Q1 2026 in Review

Stratos Wealth Partners increased its Novartis (NVS) stake by 1.4% in Q1 2026, buying an estimated $20.4K and bringing the position to 9,719 shares worth $1.48M. The position accounts for 0.02% of the portfolio, ranked #656.

Stratos Wealth Partners first reported a position in NVS in Q2 2014 and has held it in 48 quarters since. The position peaked at $3.67M in Q3 2017. 1,590 funds tracked by Wall St. Rank hold NVS as of Q1 2026.

  • Stratos Wealth Partners held 9,719 shares of Novartis worth $1.48M as of Q1 2026.
  • Stratos Wealth Partners bought 133 Novartis shares in Q1 2026, an estimated $20.4K.
  • Novartis made up 0.02% of Stratos Wealth Partners's portfolio in Q1 2026, its #656 holding.
  • Stratos Wealth Partners first reported a position in Novartis in Q2 2014 and has held it in 48 quarters since.
  • Stratos Wealth Partners's Novartis position peaked at $3.67M in Q3 2017.
  • 1,590 funds tracked by Wall St. Rank held Novartis as of Q1 2026.

Based on Stratos Wealth Partners's 13F filing for Q1 2026, filed 28 Apr 2026.